statement

Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3 ATTAIN-OSA trial for adults with obesity and moderate-to-severe obstructive sleep apnea.

A statement by Eli Lilly. Statements are as reported by the cited publishers — not verified by DecisionGateway.

Eli Lilly says Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3 ATTAIN-OSA trial for adults with obesity and moderate-to-severe obstructive sleep apnea.
pattystraphousePublished 2026-11-09 Read source

Discussion

0/2000

Related claims

More claims by Eli Lilly

No other claims by this actor on record.